Formulation

Presspart will still be responsible for the manufacturing of the Sunriser device.

Advancements in therapeutic modalities are necessitating change in drug delivery to help negate some of the expense of development and manufacturing.

Polyplus’ LipidBrick is designed to expand the scope of lipid nanoparticle formulation usage in mRNA therapeutics and vaccine development.

Under a technology licensing agreement with Bhami Research Laboratory, Catalent intends to develop formulations that will allow for the delivery of high-concentration biologics subcutaneously.

Particle engineering can be a resourceful tool to advance drug candidates by offering drug delivery innovation.

Companies need to consider and address formulation challenges to employ a successful reformulation strategy.

There are many benefits of employing a reformulation strategy, but companies must also overcome a variety of challenges too.

Research into oncolytic viruses potentiated by stem cells shows promise for treating cancer.

Manufacturing and processing challenges surrounding mRNA can be overcome in order to realize the true potential of a technology 30 years in the making.

Using an orthogonal approach to lipid nanoparticle analysis can increase the odds of project success.

Experts divulge where the industry is outsourcing most frequently, when companies should outsource more, and when performing tasks in-house might be best.

Battles against antibiotic-resistant bacteria can be won with bacteriophages.

With high-concentration biologics, careful selection of excipients in formulation is crucial for reducing viscosity without destabilizing the protein.

Careful selection is essential for achieving viscosity reduction without protein destabilization.

New and emerging biotherapeutic molecules drive the need for innovative solutions to meet cold-chain requirements.

Autologous tumor cells engineered for immune system stimulation can target unique metabolic, genomic, and phenotypic characteristics of cancer cells.

Crystec and Biosidus have joined forces to enhance the delivery and performance of biotherapeutics.

EMA's CHMP has approved two new manufacturing sites and a ready-to-use formulation of Comirnaty.

The complexity of newer biotherapeutic molecules calls for alternative drug delivery strategies.

The intranasal route of administration is showing clinical promise, particularly for COVID-19, but there are multiple hurdles to overcome to ensure successful formulation.

Moderna announced a collaboration to develop a new mRNA therapeutic for Crigler-Najjar Syndrome Type 1 at no cost to patients.

Establishing analytical workflows for complex biopharmaceutical molecules can help predict their risk of degradation.

Syngene International appoints two US-based executives to senior level positions.

Advances in technology are accelerating the development and manufacture of subunit vaccines, an established class of vaccines.

Researchers from the Chalmers University of Technology and AstraZeneca have developed a new method of detecting and testing lipid nanoparticles.